Price T Rowe Associates Inc Karyopharm Therapeutics Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Karyopharm Therapeutics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 97,100 shares of KPTI stock, worth $86,419. This represents 0.0% of its overall portfolio holdings.
Number of Shares
97,100
Previous 95,091
2.11%
Holding current value
$86,419
Previous $144,000
41.67%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding KPTI
# of Institutions
115Shares Held
65.3MCall Options Held
500KPut Options Held
99K-
Vanguard Group Inc Valley Forge, PA7.65MShares$6.81 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.1MShares$4.54 Million0.56% of portfolio
-
Eversept Partners, LP New York, NY4.99MShares$4.44 Million0.33% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.32MShares$3.84 Million0.01% of portfolio
-
Black Rock Inc. New York, NY4.17MShares$3.71 Million0.0% of portfolio
About Karyopharm Therapeutics Inc.
- Ticker KPTI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,806,600
- Market Cap $71M
- Description
- Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...